About Aprexis
Aprexis helps health plans manage medication use after prescriptions are written. Customers can operate its software through their own pharmacy teams or delegate the clinical work to Aprexis. It serves Medicare, Medicaid, and commercial plans. Its four offerings include MTM-Resolve, STAR-Resolve, and Adherence-Resolve.
Aprexis offers a software platform and fully managed pharmacy care services. Its programs target quality scores, medication adherence, and avoidable medical and pharmacy spending. The company is based in Montpelier, Vermont. Michael Howe is chief executive officer.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Sep 26, 2023 | Oct 1, 2024amended Nov 11, 2026 | $2,215,504fully sold | 16 | $138K | DebtRule 506(b) | Form D/A ↗1 earlier filing |
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Why Investors Backed Aprexis
Aprexis sells pharmacy care software and services to health plans. It aims to connect medication management with plan quality and spending goals. Aprexis argues that resolving drug therapy problems can lower avoidable medical and pharmacy costs.
The problem it targets
In Aprexis's view, pharmacy teams must improve member outcomes and quality scores while controlling costs. These departments often work with limited resources as complexity rises. Medication support must continue after prescribing, including help with correct use, treatment adjustments, and monitoring.
What the product does
The platform analyzes health insurance claims to identify members, quality measures, and spending at risk. Configurable workflows place clinical alerts inside pharmacists' existing processes. Reporting serves pharmacy, quality, and executive teams. Under delegated service, Aprexis runs clinical programs end to end, including outreach and reporting.
Who backs it
A CMS Innovation Grant supported development of Aprexis's original platform for managing medication use. Aprexis later expanded from that platform into a broader pharmacy care management partner.
We wrote this summary from public statements by Aprexis and its investors. It is not investment advice.
Leadership Team
Executive officers and directors listed on Aprexis's Form D filed Nov 11, 2026.